retatrutide release date Commercial Availability Timeline: Key Milestones and Costs Retatrutide Significantly Reduces Visceral Fat

Registered dietitian Ayla Barmmer told The New York Post that 15% of her GLP-1 patients have encountered fertility challenges, with 40% of that group experiencing irregular menstrual cycles, delayed ovulation, or declining sperm quality, outcomes likely tied to nutrient deficiencies resulting from rapid weight loss

Multiple studies on GLP-1 receptor agonists have documented that approximately 25-40% of total weight lost comes from lean body mass rather than fat

10.1126/scitranslmed.aan0972 [DOI] [PubMed] [Google Scholar] 13.Andreassen SN, Toft-Bertelsen TL, Wardman JH et al (2022) Transcriptional profiling of transport mechanisms and regulatory pathways in rat choroid plexus

Am J Physiol Endocrinol Metab 278: E1010-1018, 2000

Bioengineering the metabolic network of CAR T cells with GLP-1 and urolithin A increases persistence and long-term anti-tumor activity

other GLP-1s side effect comparison What we dont know yet: Long-term safety The phase 2 clinical trials show promising results for retatrutide